Annamaria Brioli

4.5k total citations
72 papers, 2.2k citations indexed

About

Annamaria Brioli is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Annamaria Brioli has authored 72 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Hematology, 47 papers in Molecular Biology and 30 papers in Oncology. Recurrent topics in Annamaria Brioli's work include Multiple Myeloma Research and Treatments (61 papers), Protein Degradation and Inhibitors (33 papers) and Cancer Treatment and Pharmacology (12 papers). Annamaria Brioli is often cited by papers focused on Multiple Myeloma Research and Treatments (61 papers), Protein Degradation and Inhibitors (33 papers) and Cancer Treatment and Pharmacology (12 papers). Annamaria Brioli collaborates with scholars based in Italy, United Kingdom and Germany. Annamaria Brioli's co-authors include Michèle Cavo, Gareth J. Morgan, Elena Zamagni, Paola Tacchetti, Lorenzo Melchor, Faith E. Davies, Martin Kaiser, Stefano Fanti, Cristina Nanni and Lucia Pantani and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Annamaria Brioli

67 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Annamaria Brioli Italy 20 1.8k 1.3k 954 255 187 72 2.2k
Thomas Moehler Germany 25 1.4k 0.8× 1.1k 0.8× 739 0.8× 281 1.1× 148 0.8× 69 2.1k
Sarah Waheed United States 22 1.7k 0.9× 1.4k 1.1× 935 1.0× 219 0.9× 156 0.8× 69 2.0k
María Teresa Cibeira Spain 23 1.3k 0.7× 1.3k 1.0× 709 0.7× 398 1.6× 105 0.6× 91 2.0k
Parameswaran Venugopal United States 21 1.1k 0.6× 684 0.5× 412 0.4× 482 1.9× 113 0.6× 130 1.9k
Martin Kropff Germany 26 2.5k 1.4× 2.1k 1.6× 1.7k 1.7× 368 1.4× 108 0.6× 69 3.1k
Álvaro Aguayo Mexico 19 867 0.5× 933 0.7× 506 0.5× 501 2.0× 243 1.3× 46 1.8k
A. John Ashcroft United Kingdom 16 949 0.5× 663 0.5× 913 1.0× 156 0.6× 59 0.3× 23 1.5k
Matthew Jenner United Kingdom 23 1.4k 0.8× 1.3k 1.0× 755 0.8× 200 0.8× 113 0.6× 86 1.8k
K.R. Desikan United States 18 1.6k 0.9× 997 0.8× 787 0.8× 245 1.0× 47 0.3× 31 1.9k
PR Greipp United States 21 1.6k 0.9× 1.5k 1.1× 781 0.8× 550 2.2× 55 0.3× 33 2.3k

Countries citing papers authored by Annamaria Brioli

Since Specialization
Citations

This map shows the geographic impact of Annamaria Brioli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annamaria Brioli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annamaria Brioli more than expected).

Fields of papers citing papers by Annamaria Brioli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annamaria Brioli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annamaria Brioli. The network helps show where Annamaria Brioli may publish in the future.

Co-authorship network of co-authors of Annamaria Brioli

This figure shows the co-authorship network connecting the top 25 collaborators of Annamaria Brioli. A scholar is included among the top collaborators of Annamaria Brioli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annamaria Brioli. Annamaria Brioli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ernst, Philipp, Christine M. Lohse, Michael Lauseker, et al.. (2025). Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective. Leukemia. 40(1). 29–36.
2.
Palusińska, Małgorzata, Yordan Sbirkov, Sven Stengel, et al.. (2025). Synergistic potential of CDK4/6 inhibitors and ATRA in non‐APL AML. British Journal of Haematology. 207(4). 1279–1288. 1 indexed citations
3.
Fleischmann, Maximilian, Madlen Jentzsch, Annamaria Brioli, et al.. (2024). Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia. Annals of Hematology. 104(1). 285–294. 2 indexed citations
4.
Brioli, Annamaria, Katia Mancuso, Mascha Binder, et al.. (2023). Pomalidomide combinations are a safe and effective option after daratumumab failure. Journal of Cancer Research and Clinical Oncology. 149(9). 6569–6574. 4 indexed citations
5.
Stengel, Sven, Kevin Petrie, Yordan Sbirkov, et al.. (2022). Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all‐trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia. British Journal of Haematology. 198(2). 338–348. 17 indexed citations
6.
Brioli, Annamaria, Maria Madeleine Rüthrich, Sebastian Scholl, et al.. (2022). Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort. Oncology Research and Treatment. 45(9). 494–503. 6 indexed citations
7.
Brioli, Annamaria, Herbert G. Sayer, Sebastian Scholl, et al.. (2019). The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. Annals of Hematology. 98(3). 713–722. 36 indexed citations
8.
Brioli, Annamaria, Lars‐Olof Mügge, Sebastian Scholl, et al.. (2018). Full Dose or Reduced Dose Melphalan (MEL) for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): A Single Center Analysis on 187 Consecutive Patients. Blood. 132(Supplement 1). 4625–4625. 4 indexed citations
9.
Brioli, Annamaria, Lars‐Olof Mügge, Andreas Hochhaus, & Marie von Lilienfeld‐Toal. (2017). Safety issues and management of toxicities associated with new treatments for multiple myeloma. Expert Review of Hematology. 10(3). 193–205. 8 indexed citations
10.
Brioli, Annamaria. (2016). First linevsdelayed transplantation in myeloma: Certainties and controversies. World Journal of Transplantation. 6(2). 321–321. 6 indexed citations
11.
Zamagni, Elena, Cristina Nanni, Katia Mancuso, et al.. (2015). PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma. Clinical Cancer Research. 21(19). 4384–4390. 107 indexed citations
12.
Pantani, Lucia, Annamaria Brioli, Paola Tacchetti, et al.. (2015). Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma. Expert Review of Hematology. 9(3). 315–323. 4 indexed citations
13.
Brioli, Annamaria, Lorenzo Melchor, Michèle Cavo, & Gareth J. Morgan. (2014). The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. British Journal of Haematology. 165(4). 441–454. 80 indexed citations
14.
Borsi, Enrica, Giulia Perrone, Carolina Terragna, et al.. (2014). HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment. Experimental Cell Research. 328(2). 444–455. 24 indexed citations
15.
16.
Walker, Brian A., Christopher P. Wardell, Lorenzo Melchor, et al.. (2013). Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 28(2). 384–390. 204 indexed citations
17.
Larocca, Alessandra, J. A. Child, Gordon Cook, et al.. (2013). The impact of response on bone-directed therapy in patients with multiple myeloma. Blood. 122(17). 2974–2977. 18 indexed citations
18.
19.
Zamagni, Elena, Patrizia Tosi, Paola Tacchetti, et al.. (2011). Long-term results of thalidomide and dexamethasone (thal–dex) as therapy of first relapse in multiple myeloma. Annals of Hematology. 91(3). 419–426. 10 indexed citations
20.
Cavo, Michèle, Elena Zamagni, Paola Tacchetti, et al.. (2009). Single or Double Autologous Stem Cell Transplantation Before and After the Era of Novel Agents. Clinical Lymphoma & Myeloma. 9. S51–S52.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Moehler Breakdown of academic impact, for papers by Sarah Waheed Breakdown of academic impact, for papers by María Teresa Cibeira Breakdown of academic impact, for papers by Parameswaran Venugopal Breakdown of academic impact, for papers by Martin Kropff Breakdown of academic impact, for papers by Álvaro Aguayo Breakdown of academic impact, for papers by A. John Ashcroft Breakdown of academic impact, for papers by Matthew Jenner Breakdown of academic impact, for papers by K.R. Desikan Breakdown of academic impact, for papers by PR Greipp
Rankless by CCL
2026